

GETINGE GROUP

Interim report

January – March 2013

17 April 2013

Johan Malmquist, CEO

Ulf Grunander, CFO

Q1 2013 - Trends in organic order intake

	2013			
	YTD			
	MS	EC	IC	TOT
Western Europe	-6.5%	-3.9%	-10.7%	-6.7%
USA and Canada	9.6%	-5.8%	5.5%	4.9%
Rest of the world	17.9%	-1.9%	-5.2%	9.6%
Total	7.5%	-4.2%	-4.6%	1.8%

Q1 2013 - Consolidated results

	2013	2012	
	YTD	YTD	Change %
Net sales, SEK million	5 664	5 246	8.0 %
Gross margin	52.0 %	52.5 %	-0.5 %
Operating cost, SEK million	-2 306	-2 050	12.5 %
EBITA before restructuring	792	854	-7.3 %
EBITA margin	14.0 %	16.3 %	-2.3 %
Restructuring cost	240	0	
Net financial items	-148	-134	
Profit before tax	252	570	-55.8 %

Q1 2013 - Medical Systems

	2013	2012	
	YTD	YTD	Change %
Net sales, SEK million	2 804	2 689	4.3 %
Gross margin %	59.9 %	58.3 %	1.6 %
Operating cost, SEK million	-1 367	-1 269	7.7 %
EBITA before restructuring	429	424	1.2 %
EBITA margin	15.3 %	15.8 %	-0.5 %
EBITA Adjusted*	490	424	15,6 %

*excluding Med Device Tax and currency adjusted


Q1 2013 - Medical Systems Highlights

Integration of Atrium on track. Continued good performance

Restructuring activities in the Cardiovascular division proceeding as planned

Acquisition of US-based LAAX Inc.

Launch of MIRA-i



Q1 2013 - Extended Care

	2013	2012	
	YTD	YTD	Change %
Net sales, SEK million	1 721	1 463	17.6 %
Gross margin %	48.8 %	52.6 %	-3.8 %
Operating cost, SEK million	-576	-451	27.7 %
EBITA before restructuring	295	339	-13.0 %
EBITA margin	17.1 %	23.2 %	-6.1 %
EBITA Adjusted*	326	339	-3,8 %

*excluding Med Device Tax and currency adjusted

Q1 2013 - Extended Care Highlights

Transfer of production from Sweden and Germany to LCC

Integration of TSS proceeding as planned

Launch of new products – Carevo and Evolve



Q1 2013 - Infection Control

	2013	2012	
	YTD	YTD	Change %
Net sales, SEK million	1 139	1 094	4.1 %
Gross margin %	37.8 %	38.1 %	-0.3 %
Operating cost, SEK million	-365	-328	11.3 %
EBITA before restructuring	69	91	-24.2 %
EBITA margin	6.1 %	8.3 %	-2.2 %
EBITA Adjusted*	107	91	17,6 %

*excluding Med Device Tax and currency adjusted

Q1 2013 – Infection Control Highlights

Acquisition of Turkish market leader
Trans Medikal Inc.

Extensive activities program initiated to
significantly improve the business area's
profitability



Financials Q1

	2013	2012
	YTD	YTD
Cash flow from operation, SEK million	366	722
Cash conversion, %	42.5%	64.2%
Net Debt, SEK million	18 395	16 325
Equity, SEK million	15 052	14 872
Equity/assets ratio, %	35.1%	37.3%
Net debt/equity ratio, multiple	1.22	1.10

Outlook 2013

Outlook 2013

- Organic revenue growth is expected to be comparable to 2012 level or slightly better.
- Earnings growth to remain favorable excluding restructuring charges but including effects of the US Medical Device Tax and negative currency hedging effects.
- The continued strengthening of the Swedish krona is estimated to result in negative currency translation effects of approx. 300 Mkr for the full year at prevailing exchange rates.
- Earnings growth will be stronger in H2 compared to H1.

Q&A

Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.